Does Blue Cross Blue Shield of Arizona Cover Novolog?

How BCBSAZ Formulary Placement Works for Novolog

Blue Cross Blue Shield of Arizona organizes covered medications into a tiered formulary. Drugs on lower tiers carry smaller copays, while higher tiers mean greater out-of-pocket expense. The exact tier for Novolog shifts by plan type (HMO, PPO, EPO) and by plan year, so confirming your current formulary document is the most reliable step you can take.

In most 2025 and 2026 BCBSAZ commercial plans, Novolog sits on the preferred brand tier. That placement means the insurer has negotiated a rebate with Novo Nordisk and passes part of that savings along as a lower copay compared to non-preferred brands. The American Diabetes Association (ADA) Standards of Care recommend rapid-acting insulin analogs like insulin aspart for mealtime glucose control in both Type 1 and Type 2 diabetes, reinforcing the clinical rationale behind formulary inclusion [1]. A 2020 Cochrane review of 10 randomized trials (N=2,751) found that rapid-acting analogs reduced postprandial glucose excursions by 17 mg/dL compared to regular human insulin, with no increase in severe hypoglycemia [2].

If your plan places Novolog on Tier 3 (non-preferred brand), ask your prescriber whether a Tier 2 biosimilar insulin aspart could work. The FDA approved the first interchangeable biosimilar insulin aspart in 2020 [3], and BCBSAZ has moved some biosimilars to a lower cost-sharing tier.

Arizona's Insulin Copay Cap and What It Means for You

Arizona became one of the first states to legislate insulin affordability. Under ARS 20-826.04, state-regulated health plans cannot charge more than $75 for a 30-day supply of any covered insulin product [4]. This law took effect in 2024 and applies to individual and small-group plans regulated by the Arizona Department of Insurance and Financial Institutions (ADIFI).

The cap does not apply to self-funded employer plans (governed by ERISA and federal law), nor does it apply to Medicare Part D. For Medicare enrollees, the Inflation Reduction Act (IRA) of 2022 separately caps insulin copays at $35 per month per covered insulin [5]. The result: most BCBSAZ members, whether on a state-regulated plan or a Medicare Advantage plan, now pay well under $100 per month for Novolog.

One exception to watch for: high-deductible health plans (HDHPs) paired with a Health Savings Account. Some HDHPs must apply the full cost of insulin toward the deductible before the copay cap activates, though IRS Notice 2019-45 allows HDHPs to cover insulin below the deductible if the plan elects to do so [6]. Confirm with your HR department or BCBSAZ member services (number on the back of your card) whether your HDHP applies the cap from day one.

Prior Authorization and Step Therapy Requirements

Most BCBSAZ commercial plans do not require prior authorization (PA) for Novolog when prescribed for Type 1 diabetes. For Type 2 diabetes, some plans enforce step therapy: the insurer may require documentation that you tried metformin, a sulfonylurea, or basal insulin before approving a rapid-acting analog.

When PA is required, your prescriber submits clinical documentation showing medical necessity. The ADA's 2025 Standards of Care state that mealtime rapid-acting insulin should be initiated "when fasting glucose targets are met but A1C remains above goal, indicating postprandial hyperglycemia" [1]. Citing this guideline in the PA request strengthens the case.

BCBSAZ typically processes PA requests within 72 hours for standard requests and 24 hours for urgent requests. If denied, you have the right to an internal appeal and, after that, an external review through ADIFI. The denial letter will include instructions.

A practical tip: ask your pharmacy to run a test claim before your first fill. This confirms whether PA is needed and tells you the exact copay before you leave the counter.

What You Will Pay Out of Pocket

Your cost for Novolog through BCBSAZ depends on three variables: formulary tier, deductible status, and pharmacy type.

For a preferred brand tier with a $30 to $60 copay structure (common in BCBSAZ PPO plans), expect to pay $30 to $60 per 30-day supply after meeting any applicable deductible. If the Arizona copay cap applies to your plan, your cost will not exceed $75 regardless of the tier.

Using a preferred pharmacy matters. BCBSAZ contracts with pharmacy networks, and filling at an out-of-network pharmacy can double or triple your copay. Mail-order pharmacy options through BCBSAZ often provide a 90-day supply for the cost of two monthly copays, saving roughly 33% over three months.

For uninsured or underinsured patients in Arizona, Novo Nordisk's patient assistance program (PAP) provides Novolog at no cost to individuals earning below 400% of the federal poverty level [7]. The program requires an application and prescriber signature. Separately, Novo Nordisk's "My$99Insulin" program caps the cost of a 30-day supply of any Novo Nordisk insulin at $99 for cash-paying customers, no insurance needed [7].

According to a 2023 study in Diabetes Care (N=1,022 insulin-dependent adults), out-of-pocket costs above $50 per month were associated with a 2.3-fold increase in insulin rationing behavior [8]. Cost is a clinical variable, not just a financial one.

Novolog vs. Biosimilar Insulin Aspart: Formulary Implications

The FDA approved insulin aspart injection (Kixelle, by Biocon/Viatris) as an interchangeable biosimilar to Novolog in 2020 [3]. Interchangeable status means a pharmacist in Arizona can substitute the biosimilar for Novolog at the point of dispensing without contacting the prescriber, unless the prescriber writes "Dispense as Written."

BCBSAZ has placed biosimilar insulin aspart on a lower tier than brand Novolog in several 2025 and 2026 plan designs. If your plan follows this pattern, switching to the biosimilar could reduce your copay by $10 to $30 per fill. Clinical data from the INSTRIDE studies showed equivalent A1C reduction (difference of 0.03%, 95% CI: -0.14 to 0.20) and comparable hypoglycemia rates between biosimilar insulin aspart and Novolog over 52 weeks [9].

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "Biosimilar insulins are as safe and effective as their reference products. The barriers to adoption are primarily perceptual, not clinical" [10]. If cost is a concern and your plan offers a lower-tier biosimilar, discuss the switch with your prescriber.

How to Verify Your Specific BCBSAZ Novolog Coverage

Formularies change annually (and sometimes mid-year). The most reliable way to confirm Novolog coverage under your BCBSAZ plan is a three-step process.

First, log into the BCBSAZ member portal and search the formulary drug list for "insulin aspart" or "Novolog." The portal will display the tier, any PA requirements, quantity limits, and step therapy rules specific to your plan. Second, call BCBSAZ member services and ask for a benefits verification for Novolog FlexPen or vial (specify the formulation your prescriber ordered). Write down the reference number for the call. Third, ask your pharmacy to run a test claim, which will show the exact copay and any flags before you commit to filling.

Formulary tier placement is driven by rebate negotiations between BCBSAZ and Novo Nordisk. The Academy of Managed Care Pharmacy (AMCP) reports that insulins are among the most frequently renegotiated drug classes, with tier changes occurring in 38% of commercial plans between successive plan years [11]. Do not assume last year's copay will hold.

Alternatives If Novolog Is Not Covered or Too Expensive

If your BCBSAZ plan does not cover Novolog, or if the copay exceeds your budget, several clinical alternatives exist.

Insulin lispro (Humalog or its authorized generic, Insulin Lispro) is another rapid-acting analog with equivalent efficacy. A meta-analysis of 22 RCTs (N=7,432) found no statistically significant difference in A1C reduction between insulin aspart and insulin lispro (weighted mean difference: 0.01%, 95% CI: -0.05 to 0.07) [12]. BCBSAZ may place insulin lispro on a lower tier, especially the authorized generic version, which Eli Lilly launched at a 50% list price reduction [13].

Insulin glulisine (Apidra) is a third rapid-acting option, though it is less commonly preferred on formularies. ReliOn brand insulin (Novo Nordisk) is available over the counter at Walmart in Arizona for approximately $73 per vial, but this is regular human insulin (NPH and Regular), not a rapid-acting analog, and is not clinically interchangeable with Novolog for most patients on modern insulin regimens.

The Endocrine Society's 2023 clinical practice guideline recommends that "cost should be explicitly discussed at every insulin prescribing encounter, and lower-cost alternatives should be presented whenever therapeutic equivalence exists" [14].

Medicare Advantage and BCBSAZ: Special Insulin Rules

If you carry a BCBSAZ Medicare Advantage plan with Part D, different rules govern insulin coverage. Under the Inflation Reduction Act, your cost for any covered insulin is capped at $35 per month per product, effective January 2023 [5]. This cap applies in the deductible phase, coverage gap (previously the "donut hole"), and catastrophic phase.

BCBSAZ Medicare Advantage plans that participate in the CMS Part D Senior Savings Model have offered this $35 cap since 2021. The IRA made it permanent across all Part D plans. In a CMS analysis of the first year of the cap, insulin out-of-pocket spending dropped by 66% among affected beneficiaries, from a median of $572 annually to $195 [15].

Novolog is included on the CMS Model List of Covered Part D Drugs for the 2025 and 2026 plan years. BCBSAZ Medicare Advantage enrollees can verify this in their Evidence of Coverage (EOC) document or by calling the plan's dedicated Medicare line.

For dual-eligible (Medicare/Medicaid) members in Arizona, AHCCCS (the state Medicaid program) covers Novolog with no copay for most recipients.

Filing an Appeal If Novolog Is Denied

A coverage denial does not end the conversation. BCBSAZ must provide written notice explaining the reason for denial and your appeal rights. The internal appeal process typically takes 30 days for standard cases and 72 hours for expedited (urgent medical need) cases.

Your prescriber should submit a letter of medical necessity citing the ADA Standards of Care [1] and documenting any prior insulin trials, A1C values, and hypoglycemia history. Include continuous glucose monitoring (CGM) data if available, as it demonstrates postprandial glucose patterns that justify rapid-acting insulin.

If the internal appeal is denied, you can request an external review through ADIFI. Arizona law requires that external reviewers be independent physicians with relevant specialty training. A 2022 Kaiser Family Foundation analysis found that 43% of external insurance appeals for prescription drugs were decided in favor of the patient [16].

The Arizona Attorney General's Health Care Consumer Assistance Program also provides free assistance with insurance disputes. That number is (602) 542-5025.